Dalton Jayne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dalton Jayne has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Anika Bushra
University of Illinois at Urbana−Champaign
2 shared publications - Joseph Irudayaraj
University of Illinois at Urbana-Champaign
2 shared publications - Xiaoxue Han
Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
2 shared publications Eden Oelze
Case Western Reserve University
1 shared publication- Gregory H. Underhill
Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
1 shared publication Thomas Locke
Biomedical Research Center in Mills Breast Cancer Institute , Carle Foundation Hospital
1 shared publication
Latest Publications
- 30 September 2026
- Published by American Chemical Society (ACS) in ACS Nano Medicine
- Vol. 1 (10) , 2644-2657
Hybrid Exosome-Bilosome Oxygen Nanobubbles for Liver Fibrosis Attenuation: Antifibrotic Efficacy Investigation in Multilineage Spheroid Platform
Liver fibrosis refers to the excessive buildup of scar tissue in the liver, which can lead to cirrhosis and hepatocellular carcinoma. It often presents with a hypoxic hepatic microenvironment and elevated oxidative stress. In this work, we present a hybrid Exosome-Bilosome Oxygen-encapsulating Nanobubble (EBON) with antifibrotic properties that has the potential to protect the liver from localized hypoxia and oxidative stress-induced hepatic damage. Grapefruit-derived exosome-like vesicles utilized here may contribute to the therapeutic potential of the EBON formulation by delivering antioxidant, anti-inflammatory, and antifibrotic cargo, alongside oxygen. EBON has a sub-50 nm size with an oxygen loading capacity of about 50 mg/L and a shelf life of half a year. EBON has demonstrated excellent protection against cellular hypoxia, reactive oxygen species, and superoxide-induced damage in LX-2 and HepG2 cell lines. Additionally, EBON has shown a significant antifibrotic effect in palmitic acid and oleic acid-induced lipotoxicity and oxidative stress-mediated fibrosis model in LX-2/HepG2 multilineage hepatic spheroids. RT-qPCR results confirmed suppression of hypoxia (HIF-1α, VEGF-A), oxidative stress (Nrf2), and pro-fibrotic signaling (α-SMA, TGF-β1, and COL1A1) associated genes in the in vitro hepatic spheroid model. Additionally, the safety profile of EBON has been established in a 14-day murine oral gavage model, validating short-term oral tolerability. We propose that the hybrid Exosome-Bilosome Oxygen encapsulating Nanobubble reported here is a proof-of-concept platform with antifibrotic potential for addressing hypoxia associated with liver fibrosis.
- 30 September 2026
- Published by American Chemical Society (ACS) in ACS Nano Medicine
- Vol. 1 (10) , 2644-2657
Hybrid Exosome-Bilosome Oxygen Nanobubbles for Liver Fibrosis Attenuation: Antifibrotic Efficacy Investigation in Multilineage Spheroid Platform
Liver fibrosis refers to the excessive buildup of scar tissue in the liver, which can lead to cirrhosis and hepatocellular carcinoma. It often presents with a hypoxic hepatic microenvironment and elevated oxidative stress. In this work, we present a hybrid Exosome-Bilosome Oxygen-encapsulating Nanobubble (EBON) with antifibrotic properties that has the potential to protect the liver from localized hypoxia and oxidative stress-induced hepatic damage. Grapefruit-derived exosome-like vesicles utilized here may contribute to the therapeutic potential of the EBON formulation by delivering antioxidant, anti-inflammatory, and antifibrotic cargo, alongside oxygen. EBON has a sub-50 nm size with an oxygen loading capacity of about 50 mg/L and a shelf life of half a year. EBON has demonstrated excellent protection against cellular hypoxia, reactive oxygen species, and superoxide-induced damage in LX-2 and HepG2 cell lines. Additionally, EBON has shown a significant antifibrotic effect in palmitic acid and oleic acid-induced lipotoxicity and oxidative stress-mediated fibrosis model in LX-2/HepG2 multilineage hepatic spheroids. RT-qPCR results confirmed suppression of hypoxia (HIF-1α, VEGF-A), oxidative stress (Nrf2), and pro-fibrotic signaling (α-SMA, TGF-β1, and COL1A1) associated genes in the in vitro hepatic spheroid model. Additionally, the safety profile of EBON has been established in a 14-day murine oral gavage model, validating short-term oral tolerability. We propose that the hybrid Exosome-Bilosome Oxygen encapsulating Nanobubble reported here is a proof-of-concept platform with antifibrotic potential for addressing hypoxia associated with liver fibrosis.
- Open Access
- 31 March 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (9) , 2416-2433
Exosome–niosome hybrid oxygen carrier for protection against acetaminophen-induced acute liver injury
Acetaminophen (APAP) overdose is one of the contributing factors for acute liver injury (ALI), caused by a hypoxic microenvironment, elevated oxidative stress, and pro-inflammatory signaling. In this work, we present an exosome–niosome hybrid oxygen carrier (ENh-OC) composed of polysorbate 80, Pluronic® F-127, medium chain triglyceride oil, and blueberry-derived exosomes. We propose that our delivery system shields the liver tissue from localized hypoxia by maintaining sustained oxygen delivery, and the antioxidant and anti-inflammatory components present in the exosomes enhance the hepatoprotective effect. The hydrodynamic diameter of ENh-OCs is 74.0 ± 30.8 nm with a zeta potential of −13.2 ± 0.5 mV, and oxygen holding capacity of 54.3 ± 1.5 mg L−1. They have a shelf life of up to 6 months at 4 °C, and an extended oxygen release profile of up to 16 hours under physiological hypoxic conditions. ENh-OCs have demonstrated excellent mitigative effects against hypoxia, reactive oxygen species, and superoxide-induced damage in LX-2 and HepG2 cell lines under 24 hours of sustained hypoxia. Additionally, ENh-OCs have shown a significant protective effect against APAP-induced cytotoxicity in LX-2spheroids when treated after 24 hours of the initial injury phase. The safety profile of ENh-OCs has been established, and efficacy in protection from APAP-induced ALI has been demonstrated in an in vivo murine model. RT-qPCR results verified downregulation of genes related to hypoxia (HIF-1α, VEGF-A), oxidative stress (Nrf2, HO-1), and inflammation (IL-1β, TNF-α) both in vitro and in vivo. Furthermore, histological analysis revealed protective effects of ENh-OCs against centrilobular necrosis and excessive immune-infiltration. We propose that the novel oxygen nanocarrier platform introduced here might act as a protective agent against APAP-induced ALI.
- 31 March 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (9) , 2416-2433
Open AccessExosome–niosome hybrid oxygen carrier for protection against acetaminophen-induced acute liver injury
Acetaminophen (APAP) overdose is one of the contributing factors for acute liver injury (ALI), caused by a hypoxic microenvironment, elevated oxidative stress, and pro-inflammatory signaling. In this work, we present an exosome–niosome hybrid oxygen carrier (ENh-OC) composed of polysorbate 80, Pluronic® F-127, medium chain triglyceride oil, and blueberry-derived exosomes. We propose that our delivery system shields the liver tissue from localized hypoxia by maintaining sustained oxygen delivery, and the antioxidant and anti-inflammatory components present in the exosomes enhance the hepatoprotective effect. The hydrodynamic diameter of ENh-OCs is 74.0 ± 30.8 nm with a zeta potential of −13.2 ± 0.5 mV, and oxygen holding capacity of 54.3 ± 1.5 mg L−1. They have a shelf life of up to 6 months at 4 °C, and an extended oxygen release profile of up to 16 hours under physiological hypoxic conditions. ENh-OCs have demonstrated excellent mitigative effects against hypoxia, reactive oxygen species, and superoxide-induced damage in LX-2 and HepG2 cell lines under 24 hours of sustained hypoxia. Additionally, ENh-OCs have shown a significant protective effect against APAP-induced cytotoxicity in LX-2spheroids when treated after 24 hours of the initial injury phase. The safety profile of ENh-OCs has been established, and efficacy in protection from APAP-induced ALI has been demonstrated in an in vivo murine model. RT-qPCR results verified downregulation of genes related to hypoxia (HIF-1α, VEGF-A), oxidative stress (Nrf2, HO-1), and inflammation (IL-1β, TNF-α) both in vitro and in vivo. Furthermore, histological analysis revealed protective effects of ENh-OCs against centrilobular necrosis and excessive immune-infiltration. We propose that the novel oxygen nanocarrier platform introduced here might act as a protective agent against APAP-induced ALI.